Day One Biopharmaceuticals Inc (DAWN)

$6.79 -0.40 (-5.56%)
Market Cap 728.79M
Revenue (ttm) 131.16M
Net Income (ttm) -95.50M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -72.81%
Debt to Equity Ratio 0.00
Volume 1,148,900
Avg Vol 1,407,260
Day's Range N/A - N/A
Shares Out 101.36M
Stochastic %K 49%
Beta -1.27
Analysts Strong Sell
Price Target $28.00

Company Profile

Day One Biopharmaceuticals, Inc., a commercial-stage company, focused on advancing class medicines for childhood and adult diseases with equal intensity in the United States. The company's lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed or refractory low-grade glioma; and Ipsen, a frontline raf-altered pLGG which is in Phase III clinical trial stage...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 484 0899
Address:
1800 Sierra Point Parkway, Suite 200, Brisbane, United States
Bio_Invest101
Bio_Invest101 Jul. 11 at 10:37 AM
$DAWN Rats leaving…
0 · Reply
Jackie_O_
Jackie_O_ Jul. 11 at 2:38 AM
$DAWN This will be bought before the end of this year... However!!! Premiums have been total 💩 Do not sell for some BS number. Wait it out. Premiums will improve and rare disease is always a hot segment. Do not give in, you can wait, you can do it!
1 · Reply
Rawbinhood
Rawbinhood Jul. 10 at 11:54 PM
$DAWN Shorts continue to cover!!
0 · Reply
pharmerdave68
pharmerdave68 Jul. 10 at 8:22 PM
$DAWN wait for it, wait for it!
0 · Reply
ngnol
ngnol Jul. 10 at 8:18 PM
$DAWN @RonIsWrong she ready to turn yet?
1 · Reply
360sage
360sage Jul. 10 at 7:32 PM
$DAWN A lot of green volume bars recently
0 · Reply
sellthedip1
sellthedip1 Jul. 10 at 4:43 PM
$DAWN clown 😂
1 · Reply
DiamondHandsBTW
DiamondHandsBTW Jul. 10 at 1:13 PM
$DAWN I don’t think m&a is near on the horizon with this one as some may say. Seems like the recent hire of head of R&D and large cash position seems to me they want to build out their ADC program.
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Jul. 10 at 1:11 PM
$DAWN got in here deep last week fundamentals and technicals look bright here. I see minimal downside and lots of upside
0 · Reply
OldManLogan
OldManLogan Jul. 10 at 11:39 AM
$ZVRA $PLX $FOLD $DAWN Had the wonderful opportunity to chat with top mgmt of a certain Massachusetts based midsized pharma yesterday and the commentary around M&A was that they would continue to look in the rare disease space. The argument was that it's easier to differentiate and add value in rare disease rather than go head to head with the REALLY big players...
0 · Reply
Latest News on DAWN
Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Jun 10, 2025, 8:30 AM EDT - 4 weeks ago

Day One Appoints Michael Vasconcelles, M.D., as Head of Research and Development

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

Jun 4, 2025, 8:59 PM EDT - 5 weeks ago

Day One Biopharmaceuticals: Strong Ojemda Potential In Q2 And Solid Rationale For DAY-301

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

May 6, 2025, 10:12 PM EDT - 2 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q1 2025 Earnings Call Transcript

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

May 6, 2025, 4:01 PM EDT - 2 months ago

Day One Reports First Quarter 2025 Financial Results and Corporate Progress

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Apr 22, 2025, 8:30 AM EDT - 2 months ago

Day One to Report First Quarter 2025 Financial Results Tuesday, May 6, 2025

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Apr 10, 2025, 11:51 PM EDT - 3 months ago

Day One Biopharmaceuticals Pullback Is A Potential Buying Opportunity

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Feb 26, 2025, 7:02 AM EST - 4 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q4 2024 Earnings Call Transcript

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Feb 25, 2025, 4:05 PM EST - 4 months ago

Day One Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Progress

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Feb 11, 2025, 8:30 AM EST - 5 months ago

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Jan 7, 2025, 11:31 AM EST - 6 months ago

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Dec 25, 2024, 7:31 AM EST - 7 months ago

Day One Biopharmaceuticals: Sales Figures In The Crosshairs

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 17, 2024, 8:30 AM EST - 7 months ago

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Nov 20, 2024, 4:30 PM EST - 8 months ago

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Nov 18, 2024, 8:30 AM EST - 8 months ago

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Oct 30, 2024, 10:57 PM EDT - 9 months ago

Day One Biopharmaceuticals, Inc. (DAWN) Q3 2024 Earnings Call Transcript

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Oct 30, 2024, 4:01 PM EDT - 9 months ago

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Oct 16, 2024, 8:30 AM EDT - 9 months ago

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Jul 30, 2024, 7:30 AM EDT - 1 year ago

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Day One Announces Oversubscribed $175.0 Million Private Placement

Jul 30, 2024, 7:00 AM EDT - 1 year ago

Day One Announces Oversubscribed $175.0 Million Private Placement

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Jul 25, 2024, 12:58 AM EDT - 1 year ago

Ipsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Jun 18, 2024, 8:30 AM EDT - 1 year ago

Day One Expands Pipeline with Potential First-in-Class Clinical-Stage Antibody Drug Conjugate (ADC) Targeting PTK7 in Solid Tumors for Adult and Pediatric Cancers

Day One Announces Sale of Priority Review Voucher for $108 Million

May 30, 2024, 8:30 AM EDT - 1 year ago

Day One Announces Sale of Priority Review Voucher for $108 Million

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

May 6, 2024, 4:30 PM EDT - 1 year ago

Day One Reports First Quarter 2024 Financial Results and Corporate Progress

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Apr 23, 2024, 3:56 PM EDT - 1 year ago

Day One's OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Feb 26, 2024, 4:30 PM EST - 1 year ago

Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Feb 1, 2024, 10:07 AM EST - 1 year ago

Navigating Day One Biopharmaceuticals' Financial Health And Clinical Prospects

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 19, 2023, 8:00 AM EST - 1 year ago

Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Nov 17, 2023, 7:00 AM EST - 1 year ago

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Nov 6, 2023, 4:30 PM EST - 1 year ago

Day One Reports Third Quarter 2023 Financial Results and Corporate Progress

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Oct 30, 2023, 8:00 AM EDT - 1 year ago

Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Sep 15, 2023, 3:21 PM EDT - 1 year ago

Day One Biopharmaceuticals: NDA Filing Decision Is An Inflection Point To Watch

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Sep 11, 2023, 9:02 PM EDT - 1 year ago

Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Aug 7, 2023, 4:30 PM EDT - 2 years ago

Day One Reports Second Quarter 2023 Financial Results and Corporate Progress

Diving Into Day One Biopharmaceuticals

Jul 23, 2023, 4:43 AM EDT - 2 years ago

Diving Into Day One Biopharmaceuticals

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Jun 12, 2023, 8:00 AM EDT - 2 years ago

Day One Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Day One Announces Pricing of Public Offering of Common Stock

Jun 6, 2023, 10:31 PM EDT - 2 years ago

Day One Announces Pricing of Public Offering of Common Stock

Day One Announces Proposed Public Offering of Common Stock

Jun 6, 2023, 4:01 PM EDT - 2 years ago

Day One Announces Proposed Public Offering of Common Stock

Cancer drugmakers rise as industry meet fuels investor interest

Jun 5, 2023, 10:59 AM EDT - 2 years ago

Cancer drugmakers rise as industry meet fuels investor interest

EVAX GTHX

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Jun 5, 2023, 8:09 AM EDT - 2 years ago

Day One Biopharmaceuticals shares jump 23% on positive results for glioma treatment

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Jun 4, 2023, 12:45 PM EDT - 2 years ago

Day One Announces New FIREFLY-1 Data for Tovorafenib (DAY101) and Initiation of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

May 30, 2023, 8:00 AM EDT - 2 years ago

Day One to Participate in the Goldman Sachs 44th Annual Healthcare Conference

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 8:30 PM EDT - 2 years ago

CORRECTION -- Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

May 25, 2023, 5:00 PM EDT - 2 years ago

Day One Announces Tovorafenib (DAY101) Data and Additional Abstracts to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

May 1, 2023, 9:00 AM EDT - 2 years ago

Day One Reports First Quarter 2023 Financial Results and Corporate Progress

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Apr 26, 2023, 9:31 AM EDT - 2 years ago

Day One Announces Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

Apr 12, 2023, 8:00 AM EDT - 2 years ago

Day One Announces Upcoming Presentation at 19th European Association of Dermato-Oncology (EADO) Congress

Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns

Apr 7, 2023, 7:37 AM EDT - 2 years ago

Day One Biopharmaceuticals: Strong Potential, Price Drop Opportunity, Some Concerns

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

Mar 6, 2023, 4:30 PM EST - 2 years ago

Day One Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Progress

Day One to Participate in the Cowen 43rd Annual Health Care Conference

Feb 27, 2023, 8:00 AM EST - 2 years ago

Day One to Participate in the Cowen 43rd Annual Health Care Conference

Day One to submit its glioma drug to the FDA this year

Jan 9, 2023, 8:30 AM EST - 2 years ago

Day One to submit its glioma drug to the FDA this year

Bio_Invest101
Bio_Invest101 Jul. 11 at 10:37 AM
$DAWN Rats leaving…
0 · Reply
Jackie_O_
Jackie_O_ Jul. 11 at 2:38 AM
$DAWN This will be bought before the end of this year... However!!! Premiums have been total 💩 Do not sell for some BS number. Wait it out. Premiums will improve and rare disease is always a hot segment. Do not give in, you can wait, you can do it!
1 · Reply
Rawbinhood
Rawbinhood Jul. 10 at 11:54 PM
$DAWN Shorts continue to cover!!
0 · Reply
pharmerdave68
pharmerdave68 Jul. 10 at 8:22 PM
$DAWN wait for it, wait for it!
0 · Reply
ngnol
ngnol Jul. 10 at 8:18 PM
$DAWN @RonIsWrong she ready to turn yet?
1 · Reply
360sage
360sage Jul. 10 at 7:32 PM
$DAWN A lot of green volume bars recently
0 · Reply
sellthedip1
sellthedip1 Jul. 10 at 4:43 PM
$DAWN clown 😂
1 · Reply
DiamondHandsBTW
DiamondHandsBTW Jul. 10 at 1:13 PM
$DAWN I don’t think m&a is near on the horizon with this one as some may say. Seems like the recent hire of head of R&D and large cash position seems to me they want to build out their ADC program.
0 · Reply
DiamondHandsBTW
DiamondHandsBTW Jul. 10 at 1:11 PM
$DAWN got in here deep last week fundamentals and technicals look bright here. I see minimal downside and lots of upside
0 · Reply
OldManLogan
OldManLogan Jul. 10 at 11:39 AM
$ZVRA $PLX $FOLD $DAWN Had the wonderful opportunity to chat with top mgmt of a certain Massachusetts based midsized pharma yesterday and the commentary around M&A was that they would continue to look in the rare disease space. The argument was that it's easier to differentiate and add value in rare disease rather than go head to head with the REALLY big players...
0 · Reply
pharmerdave68
pharmerdave68 Jul. 9 at 8:52 PM
$DAWN I like that close!
0 · Reply
sellthedip1
sellthedip1 Jul. 9 at 8:00 PM
$DAWN this brother knows something
0 · Reply
RideDaLightning
RideDaLightning Jul. 9 at 6:07 PM
$DAWN $7 close today
0 · Reply
ngnol
ngnol Jul. 9 at 3:08 PM
$DAWN we only want 2billion!
0 · Reply
RideDaLightning
RideDaLightning Jul. 9 at 2:16 PM
$DAWN we need a rocket GIF
0 · Reply
Redposition
Redposition Jul. 9 at 1:14 PM
$DAWN $25
0 · Reply
Bio_Invest101
Bio_Invest101 Jul. 9 at 11:54 AM
$DAWN So many small and big deals lately in biotech sector but this little nugget has been acting quite strangely. https://www.cnbc.com/2025/07/09/merck-to-acquire-verona-pharma.html
0 · Reply
pharmerdave68
pharmerdave68 Jul. 8 at 1:19 AM
$DAWN I like the after hours action.
0 · Reply
Bigeyes2
Bigeyes2 Jul. 7 at 11:16 PM
$DAWN 👀
0 · Reply
Bio_Invest101
Bio_Invest101 Jul. 5 at 5:31 PM
$IRWD https://www.fiercebiotech.com/biotech/why-emboldened-activist-investors-are-taking-fight-biotechs Why 'emboldened' investors are taking the fight to biotechs $DAWN
0 · Reply
topstockalerts
topstockalerts Jul. 4 at 4:18 PM
$DAWN primed for continuation.. 🚨----🏦----🚨
0 · Reply
Damian23
Damian23 Jul. 4 at 3:23 PM
$DAWN Shares Outstanding: ~101 million (latest SEC filing and financial sources). Cash Position: ~$473 million (Q1 2025, as previously stated). Revenue (2025E): $122 million (annualized from Q1 2025). Peak Sales Potential: $750 million (OJEMDA, consensus estimate). Gross Margin: ~90% (specialty pharma, confirmed by low COGS). EBITDA Margin at Peak: 30% (specialty/rare disease pharma average). Discount Rate (WACC): 10% (reflects sector risk). Terminal Growth Rate: 2%. Tax Rate: 15% (orphan drug incentives, then normalizing). No debt.
1 · Reply